Published online Apr 7, 2024. doi: 10.3748/wjg.v30.i13.1899
Peer-review started: January 4, 2024
First decision: January 17, 2024
Revised: January 29, 2024
Accepted: March 13, 2024
Article in press: March 13, 2024
Published online: April 7, 2024
Processing time: 89 Days and 15.2 Hours
Although commonly perceived as disease of the gastrointestinal system, inflammatory bowel disease can affect other organ systems, including cardiovascular, potentially leading to increased morbidity and mortality. Growth-differentiation factor-15 (GDF-15) is often over-expressed in stress conditions, including inflammation, malignancies, heart failure, and myocardial ischemia. In fact, elevated serum concentrations of GDF-15 have been linked to poor outcomes in conditions with diverse pathogenesis, such as colorectal cancer and heart failure.
As serum concentrations of GDF-15 were shown to be an independent predictor of poor outcomes in diverse ailments, we aimed to explore whether such association is present in the setting of inflammatory bowel disease (IBD) and its consequences. Establishing the role of GDF-15 in IBD might be relevant since poor long-term outcomes in IBD population are currently not fully elucidated.
To establish whether serum levels of GDF-15 in patients with IBD are different then in the healthy controls. Furthermore, we aimed to establish whether GDF-15 level correlate with disease severity, thus providing a rationale for the future assessment of its prognostic role in IBD. Finally, we investigated if association between indices of anemia and GDF-15 serum levels exists in this population.
In this cross-sectional study, patients with IBD and healthy age- and sex-matched participants underwent an extensive diagnostic workup. IBD group also underwent colonoscopy with subsequent histopathological analysis, and the disease activity was assessed using well-established clinical and endoscopic scoring systems. GDF-15 serum concentrations were determined using electrochemiluminescence immunoassay.
The principal findings of the present study reveal significantly elevated levels of GDF-15 in patients with IBD compared to the control group, and these levels increase with greater disease severity. Since no similar data have been previously published, the reasons behind this observation remain elusive. Nevertheless, considering the independent association between GDF-15 and indices of anemia, it is plausible that pathophysiological changes in anemia and iron metabolism might, to some extent, explain the observed difference.
This study marks the first demonstration of significantly elevated serum concentrations of GDF-15 in patients with IBD. While mechanistic studies and prospective trials are essential for firm conclusions, these preliminary findings suggest that exploring the role of GDF-15 as a biomarker in IBD could be worthwhile.
Future research should delve into the prognostic role of GDF-15, with a specific focus on its relationship with disease severity. Furthermore, investigating the mechanisms underlying these preliminary results will contribute to a deeper understanding of the role of GDF-15 in IBD.